XML 78 R51.htm IDEA: XBRL DOCUMENT v2.4.1.9

Summary of Revenue Recognized under Various Agreements (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Product Information [Line Items]
Milestone revenue	$ 8,000us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized			$ 5,400us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized								$ 3,000us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Total revenues	2,277us-gaap_Revenues	2,209us-gaap_Revenues	3,048us-gaap_Revenues	3,498us-gaap_Revenues	2,847us-gaap_Revenues	2,927us-gaap_Revenues	3,392us-gaap_Revenues	2,085us-gaap_Revenues	11,032us-gaap_Revenues	11,251us-gaap_Revenues	9,714us-gaap_Revenues
Grant revenue									2,688us-gaap_RevenueFromGrants	5,138us-gaap_RevenueFromGrants	3,939us-gaap_RevenueFromGrants
National Institutes Of Health
Product Information [Line Items]
Grant revenue									593us-gaap_RevenueFromGrants / us-gaap_TypeOfArrangementAxis = dvax_NationalInstitutesOfHealthMember	1,035us-gaap_RevenueFromGrants / us-gaap_TypeOfArrangementAxis = dvax_NationalInstitutesOfHealthMember	368us-gaap_RevenueFromGrants / us-gaap_TypeOfArrangementAxis = dvax_NationalInstitutesOfHealthMember
Astra Zeneca
Product Information [Line Items]
Initial payment									681us-gaap_DeferredRevenueAdditions / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember	720us-gaap_DeferredRevenueAdditions / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember	720us-gaap_DeferredRevenueAdditions / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember
Subsequent payment									2,554dvax_SubsequentPayment / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember
Milestone revenue									2,174us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember	2,507us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember	2,462us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember
Total revenues									5,409us-gaap_Revenues / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember	3,227us-gaap_Revenues / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember	3,182us-gaap_Revenues / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember
Glaxo Smith Kline
Product Information [Line Items]
Initial payment									2,524us-gaap_DeferredRevenueAdditions / us-gaap_CounterpartyNameAxis = dvax_GlaxoSmithKlineMember	1,702us-gaap_DeferredRevenueAdditions / us-gaap_CounterpartyNameAxis = dvax_GlaxoSmithKlineMember	1,428us-gaap_DeferredRevenueAdditions / us-gaap_CounterpartyNameAxis = dvax_GlaxoSmithKlineMember
Total revenues									2,524us-gaap_Revenues / us-gaap_CounterpartyNameAxis = dvax_GlaxoSmithKlineMember	1,702us-gaap_Revenues / us-gaap_CounterpartyNameAxis = dvax_GlaxoSmithKlineMember	1,428us-gaap_Revenues / us-gaap_CounterpartyNameAxis = dvax_GlaxoSmithKlineMember
National Institute Of Allergy And Infectious Diseases
Product Information [Line Items]
Grant revenue									$ 2,095us-gaap_RevenueFromGrants / us-gaap_CounterpartyNameAxis = dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember	$ 4,103us-gaap_RevenueFromGrants / us-gaap_CounterpartyNameAxis = dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember	$ 3,571us-gaap_RevenueFromGrants / us-gaap_CounterpartyNameAxis = dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember

X

- Definition

Subsequent payment.

+ References

No definition available.

+ Details

Name:	dvax_SubsequentPayment
Namespace Prefix:	dvax_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_ProductInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_RevenueFromGrants
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_GlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=dvax_NationalInstitutesOfHealthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: